公开(公告)号：US20180243416A1

公开(公告)日：2018-08-30

申请号：US15906887

申请日：2018-02-27

Applicant: The Trustees of the University of Pennsylvania ,  Janssen Biotech, Inc.

Inventor： Maria P. Limberis ,  Anna P. Tretiakova ,  James M. Wilson ,  Michael Naso ,  Joost Kolkman ,  Robert Friesen ,  Qiang Wang

IPC: A61K39/42 ,  C12N7/06 ,  A61K39/145 ,  A61P31/16

Abstract: A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.

公开(公告)号：US20180222972A1

公开(公告)日：2018-08-09

申请号：US15818015

申请日：2017-11-20

Applicant: Janssen Biotech, Inc.

Inventor： Diane D. Harrison ,  Elizabeth C. Hsia ,  Lee-Lian Kim ,  Kim Hung Lo

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/395 ,  A61K31/519 ,  A61K31/4402 ,  A61K31/4706 ,  A61P19/02

CPC classification number: C07K16/241 ,  A61K9/0019 ,  A61K31/4402 ,  A61K31/4706 ,  A61K31/519 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/545 ,  A61P19/02 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Ankylosing Spondylitis (AS).

公开(公告)号：US10040842B2

公开(公告)日：2018-08-07

申请号：US14921589

申请日：2015-10-23

Applicant: Janssen Biotech, Inc.

Inventor： Steven Jacobs ,  Karyn O'Neil

IPC: C40B40/08 ,  C07K14/78 ,  C40B50/06

CPC classification number: C07K14/78 ,  C40B40/08 ,  C40B50/06

Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

公开(公告)号：US20180208669A1

公开(公告)日：2018-07-26

申请号：US15319344

申请日：2015-06-15

Applicant: The United State of America, as represented by the Secretary Dept. of Health and Human Services ,  Janssen Biotech, Inc.

Inventor： Richard W. Childs ,  Maria Berg ,  Luis Espinoza Calderon ,  Kate Sasser ,  Ricardo Attar

IPC: C07K16/28 ,  A61P35/02 ,  A61P37/00

CPC classification number: C07K16/2896 ,  A61K39/39558 ,  A61P35/02 ,  A61P37/00 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/732 ,  A61K2300/00

Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.

公开(公告)号：US20180143203A1

公开(公告)日：2018-05-24

申请号：US15845657

申请日：2017-12-18

Applicant: Janssen Biotech, Inc.

Inventor： Michael Diem ,  Steven Jacobs

IPC: G01N33/68

Abstract: Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

公开(公告)号：US20180134784A1

公开(公告)日：2018-05-17

申请号：US15813767

申请日：2017-11-15

Applicant: Janssen Biotech, Inc.

Inventor： Dennis Fitzgerald ,  Newman Yielding ,  Jay Siegel

IPC: C07K16/24 ,  A61K47/26 ,  A61K47/22 ,  A61K39/395 ,  A61K45/06 ,  A61K31/519 ,  C07K16/28 ,  A61P17/06

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61K31/519 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/545 ,  A61P17/06 ,  C07K16/28 ,  C07K16/2887 ,  C07K2317/21 ,  G01N33/00

Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US20180117150A1

公开(公告)日：2018-05-03

申请号：US15798670

申请日：2017-10-31

Applicant: Janssen Biotech, Inc.

Inventor： Michael O'Dwyer ,  Aideen Ryan

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/675 ,  A61K38/05 ,  A61K31/454 ,  A61K31/573 ,  A61K38/47 ,  A61K9/00

CPC classification number: A61K39/39558 ,  A61K9/0019 ,  A61K31/454 ,  A61K31/573 ,  A61K31/675 ,  A61K38/05 ,  A61K38/47 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2896 ,  C07K2317/73 ,  C12Y302/01035

Abstract: Provided are combination therapies comprising an anti-CD38 antibody and cyclophosphamide for CD38-positive hematological malignancies.

公开(公告)号：US09951314B2

公开(公告)日：2018-04-24

申请号：US15274749

申请日：2016-09-23

Applicant: Janssen Biotech, Inc.

Inventor： Benjamin Fryer

IPC: C12N5/00 ,  C12N5/071

CPC classification number: C12N5/0678 ,  C12N2500/34 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/19 ,  C12N2501/727 ,  C12N2506/02 ,  C12N2533/54

Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells, wherein greater than 80% of the cells in the population express markers characteristic of the definitive endoderm lineage.

公开(公告)号：US20180105785A1

公开(公告)日：2018-04-19

申请号：US15835879

申请日：2017-12-08

Applicant: Janssen Biotech, Inc.

Inventor： Daina Laniauskas ,  Joseph Hammer

IPC: C12M1/00 ,  G01N1/14 ,  B01D17/02 ,  G01N1/12

CPC classification number: C12M29/00 ,  B01D17/0214 ,  G01N1/12 ,  G01N1/14 ,  G01N2001/1418 ,  Y10T137/0318 ,  Y10T137/8593

Abstract: Devices and methods are provided for removing media from a culture vessel that decreases disruption of the interface between the cellular material and media within the vessel such that aspiration and removal of cells or cell clusters along with the media is minimized. In addition, the media fluid turbulence is decreased so as to minimize the activation or disruption of cells and cell clusters.

公开(公告)号：US20180099129A1

公开(公告)日：2018-04-12

申请号：US15835871

申请日：2017-12-08

Applicant: Janssen Biotech, Inc.

Inventor： Stephen Evans ,  Audrey Bell

IPC: A61M31/00 ,  C12M1/12 ,  C12M1/00

CPC classification number: A61M31/00 ,  A61F2/02 ,  A61M2202/09 ,  A61M2209/045 ,  C12M1/00 ,  C12M1/12

Abstract: The present invention provides a loading fixture for loading cells, cell clusters, and media to an immune-isolation device. The loading fixture permits the loading of cells into the immune-isolation device without manual manipulation of the immune-isolation device, until the loading device is opened at the point of use, thereby minimizing the risk of contamination of the immune-isolation device.